GlassScriptPhysician profile
Paige N Stephens
NPI 1801259304
$5,092.63
in general payments reported to CMS, 2019-2025
26 companies · $1,541 in 2025
The $1,541 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $92.61 · 2021: $1,292 · 2022: $835 · 2023: $555 · 2024: $236 · 2025: $1,541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,776 · Consulting Fee: $556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,775.70 |
| Consulting Fee | $555.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,564.80 | 2021-2025 | Acuvue |
| Alcon Vision LLC | $722.53 | 2019-2025 | Tryptyr, Precision 1, Eysuvis |
| Sun Pharmaceutical Industries INC. | $359.45 | 2019-2023 | Cequa |
| Glaukos Corporation | $341.44 | 2021-2025 | Photrexa Viscous and Photrexa |
| Kala Pharmaceuticals, INC. | $202.56 | 2021-2022 | |
| Ocular Therapeutix, INC. | $149.95 | 2025 | |
| Oyster Point Pharma, INC. | $147.18 | 2022-2023 | Tyrvaya |
| Horizon Therapeutics Plc | $142.55 | 2023 | Tepezza |
| Allergan, INC. | $139.21 | 2019 | |
| Hoffmann-La Roche Limited | $134.07 | 2021 | |
| Heru, INC. | $125.25 | 2022 | |
| Astellas Pharma US INC | $124.80 | 2025 | Izervay |
| Genzyme Corporation | $113.85 | 2019 | |
| Notal Vision, INC. | $106.53 | 2021-2022 | |
| Coopervision INC. | $101.79 | 2022-2023 | Clariti Contact Lens |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $96.31 | 2022-2025 | Xiidra, Miebo, Infuse |
| Abb Con-Cise Optical Group LLC | $86.18 | 2019-2025 | Contact Lens |
| Abbvie INC. | $71.33 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $67.10 | 2020-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $62.29 | 2019 | |
| Dompe US, INC. | $50.46 | 2022-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $44.87 | 2020 | |
| Eyevance Pharmaceuticals LLC | $39.55 | 2019 | |
| Aerie Pharmaceuticals, INC. | $38.04 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $31.67 | 2024-2025 | Xdemvy |
| Lkc Technologies, INC. | $28.87 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paige Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.